The collaboration addresses challenges posed by a fragmented service ecosystem that leads to duplicated efforts, delayed knowledge transfer and extended development times. By combining Calyx/Invicro’s radiochemistry and imaging biomarker solutions with BAMF Health’s advanced radiopharmaceutical facilities supporting a range of alpha, beta and gamma agents, as well as molecular imaging and treatment clinics, biotechnology and pharmaceutical companies have end-to-end resources to transition these advanced programs into clinical trials.
The project driving this partnership is the Actinium-225 Initiative, with TerraPower supplying actinium-225 and BAMF leveraging its GE HealthCare StarGuide™ SPECT/CT and dosimetry expertise to enhance research and application of actinium-225 in RLT.
This collaboration represents a significant moment for our industry because now more than ever, contract research organizations, contract manufacturing organizations, and diagnostic imaging clinics need to work together to support these complex and technically demanding RLT and IO programs. This collaboration and partnerships ease contracting and communication, streamline operations, integrate knowledge across scientific, regulatory, and operational disciplines, and provide access to the latest technology from early preclinical research through patient imaging.
“The success of Calyx/Invicro’s translational models in the CNS field is London “Our partnership with the New Haven clinic demonstrates the effectiveness of our integrated services approach. We are confident that our partnership with BAMF Health will bring that same level of innovation and acceleration to oncology,” he said. Edward HoganCOO of Calyx/Invicro.
Director of Clinical Trials at BAMF Health And Rogers“Our combined strengths with Calyx/Invicro enable us to address the unique challenges of developing radioligand and immuno-oncology therapies. This collaboration will strengthen and speed up our development process towards our mission of making precision medicines affordable and accessible to everyone,” he added.
Through this collaboration, Calyx/Invicro and BAMF Health aim to address key hurdles in the clinical translation of radioligand and immune-oncology therapies. The companies’ joint efforts highlight their commitment to advancing these therapies, redefining the standard of care for oncology and ensuring faster access to promising therapies for patients.
About Calyx / Invicro
Calyx/Invicro is a trusted global provider of scientific and medical expertise for imaging strategy, implementation and analysis in clinical trials. The combination of the two organizations creates a new global leader in providing medical imaging solutions, offering the industry’s broadest range of pre-clinical to late-phase imaging services, including imaging biomarkers, core laboratory services, analytics and software.
With operations in six countries, Calyx/Invicro helps pharmaceutical, biotechnology and contract research organizations around the world achieve their development goals in key therapeutic areas such as oncology, central nervous system and respiratory, and meets the growing demand for enhanced imaging and novel therapies in fast-growing specialties such as radiotherapy, gastroenterology, inflammation, fibrosis and mitochondrial imaging.
For more information, visit Calyx.ai and Invicro.com.
About BAMF Health
BAMF Health is the world’s first vertically integrated platform for intelligence-based precision medicine. Headquartered in Grand Rapids, MichiganBAMF Health employs cutting-edge theranostic imaging technologies to detect and treat cancer and other diseases, and conduct advanced clinical trials. Our overriding mission is to help patients be human again. Our aligned teams of data scientists, researchers, software engineers and clinicians deliver on that mission. To learn more about BAMF Health, visit www.bamfhealth.com.
Source Calyx
